CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$40.15−0.22 (-0.54%)
Close on Nov 17, 2026Market cap $3.88BP/E –Yield –
CRISPR Therapeutics cash
Cash and short-term investments held at the end of each period.
CRISPR Therapeutics's cash was $2.36B at Jun 30, 2026. For fiscal 2025 it was $1.98B, up 3.8% from the year before. Over ten years it grew 28.9% a year on average. The highest annual figure on record is $2.38B in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.98B | +3.8% |
| FY2024 | Dec 31, 2024 | $1.90B | +12.4% |
| FY2023 | Dec 31, 2023 | $1.69B | -6.7% |
| FY2022 | Dec 31, 2022 | $1.82B | -23.7% |
| FY2021 | Dec 31, 2021 | $2.38B | +40.7% |
| FY2020 | Dec 31, 2020 | $1.69B | +79.1% |
| FY2019 | Dec 31, 2019 | $943.77M | +106.7% |
| FY2018 | Dec 31, 2018 | $456.65M | +90.5% |
| FY2017 | Dec 31, 2017 | $239.76M | -24.0% |
| FY2016 | Dec 31, 2016 | $315.52M | +102.3% |
| FY2015 | Dec 31, 2015 | $155.96M | +16403.8% |
| FY2014 | Dec 31, 2014 | $945.00K | +161.8% |
| FY2013 | Dec 31, 2013 | $361.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.36B | +37.4% |
| Q1 FY2026 | Mar 31, 2026 | $2.44B | +31.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.98B | +3.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.92B | -1.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.72B | -14.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.86B | -12.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.90B | +12.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.94B | +11.3% |
| Q2 FY2024 | Jun 30, 2024 | $2.00B | +13.2% |
| Q1 FY2024 | Mar 31, 2024 | $2.11B | +11.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.69B | -6.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.74B | -8.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.77B | -14.4% |
| Q1 FY2023 | Mar 31, 2023 | $1.88B | -15.2% |
| Q4 FY2022 | Dec 31, 2022 | $1.82B | -23.7% |
| Q3 FY2022 | Sep 30, 2022 | $1.90B | -23.5% |
| Q2 FY2022 | Jun 30, 2022 | $2.07B | -20.2% |
| Q1 FY2022 | Mar 31, 2022 | $2.22B | +23.0% |
| Q4 FY2021 | Dec 31, 2021 | $2.38B | +40.7% |
| Q3 FY2021 | Sep 30, 2021 | $2.48B | +81.4% |
| Q2 FY2021 | Jun 30, 2021 | $2.59B | +174.0% |
| Q1 FY2021 | Mar 31, 2021 | $1.81B | +103.0% |
| Q4 FY2020 | Dec 31, 2020 | $1.69B | +79.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.37B | +116.9% |
| Q2 FY2020 | Jun 30, 2020 | $945.07M | +120.9% |
| Q1 FY2020 | Mar 31, 2020 | $889.71M | +103.3% |
| Q4 FY2019 | Dec 31, 2019 | $943.77M | +106.7% |
| Q3 FY2019 | Sep 30, 2019 | $629.72M | +29.2% |
| Q2 FY2019 | Jun 30, 2019 | $427.89M | +33.8% |
| Q1 FY2019 | Mar 31, 2019 | $437.55M | +28.0% |
| Q4 FY2018 | Dec 31, 2018 | $456.65M | +90.5% |
| Q3 FY2018 | Sep 30, 2018 | $487.30M | +92.2% |
| Q2 FY2018 | Jun 30, 2018 | $319.74M | +17.4% |
| Q1 FY2018 | Mar 31, 2018 | $341.77M | +17.0% |
| Q4 FY2017 | Dec 31, 2017 | $239.76M | -24.0% |
| Q3 FY2017 | Sep 30, 2017 | $253.52M | +10.9% |
| Q2 FY2017 | Jun 30, 2017 | $272.26M | – |
| Q1 FY2017 | Mar 31, 2017 | $292.02M | – |
| Q4 FY2016 | Dec 31, 2016 | $315.52M | – |
| Q3 FY2016 | Sep 30, 2016 | $228.61M | – |
See a number that looks wrong?